

Carboplatin Pharmacokinetic and Pharmacodynamic Mathematical Model for FUS-BBB Disruption in the Brain Tumour Microenvironment

Bush A. J.^a, Guo Y.^b, Arvanitis C. D.^{b,c}

^a Department of Engineering Science, University of Oxford, Oxford, U.K.

^b Woodruff School of Mechanical Engineering, Georgia Institute of Technology, Atlanta, Georgia, U.S.A.

^c Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta Georgia, U.S.A.




INTRODUCTION

- Glioblastoma Multiforme (GBM) is a highly invasive form of glioma with extremely poor prognosis and a median survival time of 14.6 months.
- The Blood-Brain Barrier (BBB) is a major obstacle to large chemotherapeutics extravasating into the brain tumour microenvironment (TME).
- Focussed Ultrasound (FUS) offers a non-invasive and transient mechanism to disrupt the BBB, increasing drug delivery to the TME.
- Previous studies [1] using Doxorubicin (543.52 g/mol) and T-DM1 (148.5 kg/mol) have shown the efficacy of this method [1]. Phase III Clinical Trials for FUS-BBB Disruption using **Carboplatin** (371.249 g/mol) are in preparation.
- Pharmacokinetic (PK) modelling was needed to **develop a mechanistic understanding of drug transport and evaluate therapeutic efficacy.**

COMPUTATION

- COMSOL v5.3a used as computational engine & MATLAB 2018a used for data analyses.
- Boundary conditions introduced based on experimentally-verified previous work by *Arvanitis et al* [1].



[ABOVE] Random-walk-generated 2D vasculature geometry. ABGDEZ data set cut-lines (red arrows) are shown within 100µm x 100µm square subdomains centred on the midpoints.

FLUID MECHANICAL & DRUG TRANSPORT PHYSICS

- Coupled physical equations through the vasculature (pipe model) and interstitium (porous media flow).
- Carboplatin transport parameters used to set boundary conditions within model.


Laminar flow: $\nabla p = \nabla[\mu(\nabla \mathbf{u} + (\nabla \mathbf{u})^T)]$, $\nabla \cdot \mathbf{u} = 0$ **Blood Vessel**

Drug transport: $\frac{\partial c_v}{\partial t} = D_b \nabla^2 c_v - \mathbf{u} \cdot \nabla c_v$

Flow in porous media: $\frac{\mu}{k} \mathbf{u} + \nabla p - \frac{\mu}{\epsilon_i} \nabla^2 \mathbf{u} = 0$ **Interstitial Space**



Drug transport: $\frac{\partial c_e}{\partial t} = D_i \nabla^2 c_e - \mathbf{u} \cdot \nabla c_e + R$

[ABOVE] Fluid-mechanical and drug transport model equations.



[ABOVE] Spatial distribution of carboplatin cytotoxicity within the tumour interstitium in response to various IV doses.

[LEFT] Cytotoxicity function; the surviving cell fraction under various extracellular carboplatin concentrations is shown [2].



[ABOVE] Spatial distribution of carboplatin extracellular concentration (top row) and intracellular concentration (bottom row) within the tumour interstitium; blood concentration within the BBB; and molar flux across the vessel walls, under control conditions and after FUS-BBB disruption at $t = 1800s$.

EXPERIMENTAL PROCEDURE

- Two phase computational study: 1) Stationary initialisation of TME physics with velocity and pressure fields. 2) Time-dependent study for drug transport, PK (cellular uptake/release) and cytotoxicity concurrent with carboplatin IV up to $t = 1800s$.


- Carboplatin CTRL parameters obtained from experimental data (literature). Data for FUS-BBB disruption conditions obtained via ratios for Doxorubicin parameters [1].
- Continuous IV infusion of carboplatin at 2.0 µg/µL at 0.33 µL/min for 30 minutes in accordance with F98 cell line dosages [2]. Molar inlet ($d = 7.34 \mu m$) flux of 2.20 mol/m²s.

RESULTS

- Parametric sensitivity analyses suggest that FUS-BBB disruption will **not critically** improve carboplatin extravasation, cellular uptake or cytotoxicity within the brain TME.
- Carboplatin IV dosage is the most critical parameter for increasing cytotoxicity. Invariance to vascular diffusivity, permeability, and porosity is clearly visible.
- Order of Magnitude analyses demonstrate decreasing trend for cellular uptake and cytotoxicity with increased FUS-BBB disruption.


DISCUSSION

- Carboplatin's MW is below the 400 Da (g/mol) threshold [3] for successful BBB extravasation, limiting the impact of FUS-BBB disruption on extravasation.
- Results suggest that **larger chemotherapeutics** molecules such as Doxorubicin and T-DM1 would **more successfully demonstrate the clinical efficacy of FUS-BBB disruption.**
- Laboratory experimentation using murine models to test validity of computational results to follow.
- It is suggested that vascular normalisation using VEGF-2 may prove an effective method for improving carboplatin uptake in the brain TME.



[ABOVE RIGHT] Parameter sensitivity ($\pm 25\%$) analysis conducted for ABGDEZ data. Sensitivity data normalised by the maximum c_i , c_e value in each ABGDEZ data set and the standard ($\pm 0\%$) parameter value. Median values taken for each parameter at $t = 1800s$.

[RIGHT] Logarithmic plots for parameter sensitivity magnitude (normalised) grouped by positive and negative results for carboplatin extracellular and intracellular concentration within the interstitium.




REFERENCES

[1] Arvanitis, Costas D., et al. "Mechanisms of enhanced drug delivery in brain metastases with focussed ultrasound-induced blood-tumour barrier disruption." Proceedings of the National Academy of Sciences 115.37 (2018): E8717-E8726.

[2] Yang, Weilian, et al. "Convection enhanced delivery of carboplatin in combination with radiotherapy for the treatment of brain tumors." Journal of neuro-oncology 101.3 (2011): 379-390.

[3] Pardridge, William M. "Drug transport across the blood-brain barrier." Journal of cerebral blood flow & metabolism 32.11 (2012): 1959-1972.



[ABOVE] Order of magnitude study for parameters sensitive to FUS-BBB disruption. Data taken from ABGDEZ medians at $t = 1800s$.



This project was completed thanks to the Laidlaw Undergraduate Research & Leadership Programme at the University of Oxford.

Special thanks to Prof. Costas D. Arvanitis and Yutong Guo at Georgia Tech for their invaluable support and supervision. Further thanks to Dr. S. Payne at the University of Oxford.

